Literature DB >> 23954638

Small proline-rich protein-1B is overexpressed in human oral squamous cell cancer stem-like cells and is related to their growth through activation of MAP kinase signal.

Yoshitaka Michifuri1, Yoshihiko Hirohashi, Toshihiko Torigoe, Akihiro Miyazaki, Jyunki Fujino, Yasuaki Tamura, Tomohide Tsukahara, Takayuki Kanaseki, Junichi Kobayashi, Takanori Sasaki, Akari Takahashi, Kenji Nakamori, Akira Yamaguchi, Hiroyoshi Hiratsuka, Noriyuki Sato.   

Abstract

Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are considered to be essential for tumor maintenance, recurrence and metastasis. Therefore, eradication of CSCs/CICs is essential to cure cancers. However, the molecular mechanisms of CSCs/CICs are still elusive. In this study, we investigated the molecular mechanism of the cell growth of oral CSCs/CICs. Oral CSCs/CICs were isolated as aldehyde dehydrogenase 1 bright (ALDH1(br)) cells by the ALDEFLUOR assay. Small proline-rich protein-1B (SPRR1B) gene was shown to be overexpressed in ALDH1(br) cells by a cDNA microarray and RT-PCR. SPRR1B was shown to have a role in cell growth and maintenance of ALDH1(br) cells by SPRR1B overexpression and knockdown experiments. To elucidate the molecular mechanism by which SPRR1B regulates cell growth, further cDNA microarray analysis was performed using SPRR1B-overexpressed cells and cells with SPRR1B knocked down by siRNA. Expression of the tumor suppressor gene Ras association domain family member 4 (RASSF4) was found to be suppressed in SPRR1B-overexpressed cells. On the other hand, the expression of RASSF4 was enhanced in cells in which SPRR1B expression was knocked down by SPRR1B-specific siRNA. RASSF4 has an RA (Ras association) domain, and we thus hypothesized that RASSF4 modulates the MAP kinase signal downstream of the Ras signal. MAP kinase signal was activated in SPRR1B-overexpressed cells, whereas the signal was suppressed in SPRR1B knocked down cells. Taken together, the results indicate that the expression of SPRR1B is upregulated in oral CSCs/CICs and that SPRR1B has a role in cell growth by suppression of RASSF4.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALDEFLUOR assay; CIC; CSC; Cancer stem cell; NOD/SCID; OSCC; Oral cancer; RASSF4; SPRR1B; cancer stem-like cell; cancer-initiating cell; non-obese diabetic/severe combined immunodeficiency; oral squamous cell carcinoma; ras association domain family member 4; small proline-rich protein-1B

Mesh:

Substances:

Year:  2013        PMID: 23954638     DOI: 10.1016/j.bbrc.2013.08.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Bioinformatic analysis identifies epidermal development genes that contribute to melanoma progression.

Authors:  Gastón Barbero; María Victoria Castro; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

2.  A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.

Authors:  Shivaprasad Patil; Annett Linge; Hannah Hiepe; Marianne Grosser; Fabian Lohaus; Volker Gudziol; Max Kemper; Alexander Nowak; Dominik Haim; Inge Tinhofer; Volker Budach; Maja Guberina; Martin Stuschke; Panagiotis Balermpas; Jens von der Grün; Henning Schäfer; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Ute Ganswindt; Claus Belka; Steffi Pigorsch; Stephanie E Combs; Simon Boeke; Daniel Zips; Korinna Jöhrens; Gustavo B Baretton; Michael Baumann; Mechthild Krause; Steffen Löck
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

3.  Identification of oral squamous cell carcinoma markers MUC2 and SPRR1B downstream of TANGO.

Authors:  Tomonori Sasahira; Miyako Kurihara-Shimomura; Hiroyuki Shimomura; Anja Katrin Bosserhoff; Tadaaki Kirita
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-23       Impact factor: 4.553

4.  RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion.

Authors:  Yong Han; Qianze Dong; Jie Hao; Lin Fu; Xu Han; Xiaoying Zheng; Enhua Wang
Journal:  Tumour Biol       Date:  2015-11-02

Review 5.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

6.  GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.

Authors:  Ryuta Inoue; Yoshihiko Hirohashi; Hiroshi Kitamura; Sachiyo Nishida; Aiko Murai; Akari Takaya; Eri Yamamoto; Masahiro Matsuki; Toshiaki Tanaka; Terufumi Kubo; Munehide Nakatsugawa; Takayuki Kanaseki; Tomohide Tsukahara; Noriyuki Sato; Naoya Masumori; Toshihiko Torigoe
Journal:  Oncotarget       Date:  2017-04-25

7.  A novel strategy for facile serum exosome isolation based on specific interactions between phospholipid bilayers and TiO2.

Authors:  Fangyuan Gao; Fenglong Jiao; Chaoshuang Xia; Yang Zhao; Wantao Ying; Yuping Xie; Xiaoya Guan; Ming Tao; Yangjun Zhang; Weijie Qin; Xiaohong Qian
Journal:  Chem Sci       Date:  2018-12-03       Impact factor: 9.825

8.  Identification of small proline-rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis.

Authors:  Zihe Zhang; Ruifeng Shi; Songlin Xu; Yongwen Li; Hongbing Zhang; Minghui Liu; Guangsheng Zhu; Chen Chen; Zhenhua Pan; Hongyu Liu; Jun Chen
Journal:  Thorac Cancer       Date:  2021-01-26       Impact factor: 3.500

Review 9.  Immune responses to human cancer stem-like cells/cancer-initiating cells.

Authors:  Yoshihiko Hirohashi; Toshihiko Torigoe; Tomohide Tsukahara; Takayuki Kanaseki; Vitaly Kochin; Noriyuki Sato
Journal:  Cancer Sci       Date:  2015-11-12       Impact factor: 6.716

10.  FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin.

Authors:  Sarah C McDermott; Christie Rodriguez-Ramirez; Sean P McDermott; Max S Wicha; Jacques E Nör
Journal:  Oncotarget       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.